With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.88675-24-5,Tetrahydrofuran-3-amine,as a common compound, the synthetic route is as follows.,88675-24-5
In a 4 mL vial was mixed the 2-chloro-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrimidine (61 mg, 0.25 mmol), tetrahydrofuran-3 -amine (22 mg, 0.25 mmol) and TEA (46 uL, 0.36 mmol) in EtOH (0.3 mL). The reaction was heated to 95 ¡ãC for 2 h before being cooled and concentrated. To the crude residue was added the 2′-bromo-6’H,8’H-spiro[chromane-4,9′-pyrido[3′,2′:4,5]imidazo[2,l-c][l,4]oxazine] (39 mg, 0.10 mmol, Preparation 86), Pd2(dba)3 (9.6 mg, 0.010 mmol), l,3,5,7-Tetramethyl-2,4,8-trioxa-6- phospha-adamantane (6.1 mg, 0.020 mmol) and CS2CO3 (74.8 mg, 0.25 mmol). THF (1 mL) and H20 (0.25 mL) were added, and the reaction was stirred at 60 ¡ãC for 18 h before being cooled to rt and concentrated. The residue was dissolved in 1 : 1 MeOH/DMSO and purified by reverse phase chromatography using a gradient of MeCN (A) and 0.1percent TFA in H20 (B) at a flow rate of 50 mL/min (0- 0.5 min 5percent A, 0.5-8.5 min linear gradient 05-100percent A, 8.7-10.7 min 100percent A, 10.7-11 min linear gradient 100-05percent A) to yield the title compound. (39 mg, 33percent); LC/MS (Table 1, method ai) Rt = 0.61 min; MS 111 ~ 457 (M+H)+. (TNF IC50= B).
As the paragraph descriping shows that 88675-24-5 is playing an increasingly important role.
Reference£º
Patent; ABBVIE INC.; BREINLINGER, Eric, C.; COX, Phil, B.; DAANEN, Jerome; DIETRICH, Justin; DJURIC, Stevan; DOMBROWSKI, Amanda, W.; FRANK, Kristine, E.; FRIEDMAN, Michael, M.; GOMTSYAN, Arthur; LI, Huan-Qui; LONGENECKER, Kenton; OSUMA, Augustine; ROWLEY, Ann, Marie; SCHMIDT, Robert; VASUDEVAN, Anil; WILSON, Noel; (378 pag.)WO2016/168641; (2016); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem